Six-Month Dermatology Care for 2,696 Patients in Iraq

November 12, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional activity or service setting. It is not a patient, diagnosis, before-and-after image, institutional endorsement or Dr. Arsy #003 treatment result.

Reader question: What did this specific study measure, in whom, at what timepoint—and which conclusions would go beyond its evidence?

Study snapshot

Study element	Reported detail
Population	2,696 patients evaluated in a combat-zone dermatology clinic in Iraq.
Design	Retrospective clinical service review categorizing dermatologic diagnoses and procedures.
Comparator	Diagnostic categories were compared descriptively within clinic attendees; there was no nondeployed control group.
Timepoint	Six months.
Key result	Eczema accounted for 17% of visits (n=462), benign neoplasms 14% (n=375), skin cancer 8% (n=205) and bacterial infections 6% (n=158). Thirty-one MRSA cases were recorded.
Funding/conflict context	The accessible abstract does not report commercial funding. No cosmetic moisturizer was evaluated.

What was actually measured?

Eczema accounted for 17% of visits (n=462), benign neoplasms 14% (n=375), skin cancer 8% (n=205) and bacterial infections 6% (n=158). Thirty-one MRSA cases were recorded.

The clinic mix demonstrates the breadth of dermatology demand, but visit proportions reflect referral and access patterns, not population prevalence.

The denominator defines the scope. A clinic series, outbreak investigation, surveillance database, questionnaire and prospective cohort answer different questions. Their percentages, rates and associations cannot be silently transferred to a different population, activity or setting.

What the result does not prove

Clinic-based selection, retrospective categorization, repeated care and no deployed population denominator limit prevalence and causal conclusions.

Observational timing and association do not automatically prove individual causation. Training load, footwear, shared surfaces, hygiene, climate, protective equipment, prior conditions, referral practices and access to care may all change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors’ conclusions, this interpretation or any product.

Condition categories should stay separate

Dryness, friction injury, dermatitis, fungal disease and bacterial infection are not interchangeable. A moisturizer may support hydration and the moisture barrier, but it does not diagnose an infection, replace medical evaluation or substitute for activity-specific prevention and infection-control measures.

For suspected infection, clinicians may need examination, microscopy, culture or other testing. Persistent spreading redness, drainage, fever, severe pain, rapidly worsening symptoms or major loss of function warrants prompt professional evaluation.

Activity details worth documenting

Which surface, footwear, glove, mat, pool, uniform, climate or training load came before the change?
Where did the problem begin, and did it change during rest, travel, deployment or a different facility?
Were skin, towels, clothing, equipment or showers shared, and how were surfaces cleaned?
How often were skin areas wet, occluded, rubbed, heated, chilled or exposed to sun?
Did the problem alter sleep, pace, attendance, training, competition or work safety?

Prevention comes before cosmetic care

Useful prevention is matched to the hazard: equipment and facility hygiene, prompt showering, clean personal textiles, well-fitted footwear, friction management, task-appropriate protective equipment, ultraviolet protection and timely clinical assessment. No single step prevents every diagnosis.

Do not share personal skin products during an outbreak and do not place workplace or environmental materials on skin to test a theory. Follow facility, occupational-health, sports-medicine and public-health instructions for contagious conditions.

Primary research and authoritative guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema or infection, relieves pain or itch, neutralizes environmental exposures, is appropriate for every person, or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace, military, sports or infection-control determination.

← Back to Doctor's Notes